Cobimetinib - Genentech

Drug Profile

Cobimetinib - Genentech

Alternative Names: Cobimetinib fumarate; Cotellic; GDC-0973; RG-7421; RO 5514041; XL-518

Latest Information Update: 01 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Exelixis; Genentech; M. D. Anderson Cancer Center; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Roche; University Hospital Tubingen
  • Class Antineoplastics; Azetidines; Fluorobenzenes; Iodobenzenes; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Phase III Colorectal cancer
  • Phase II Breast cancer; Head and neck cancer; Histiocytosis; Renal cell carcinoma; Urogenital cancer
  • Phase I/II Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 17 Nov 2017 Roche plans a phase I/II trial for Non-small cell lung cancer (Combination therapy, Metastatic disease) in Australia, South Korea, France, Spain, United Kingdom and USA in December 2017 (NCT03337698)
  • 17 Nov 2017 Phase I development in Solid tumours (Combination therapy, Late-stage disease) in is ongoing in USA, Singapore, South Korea, Germany, Canada, Australia and Spain (NCT01988896)
  • 14 Nov 2017 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Metastatic disease) in Australia (PO) (NCT03337698)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top